dr. F.Y.F.L. (Filip) de Vos

Assistant Professor - medical
dr. F.Y.F.L. (Filip) de Vos
  • Department of Medical Oncology

Research Programs

Strategic Program Cancer






1993 –   1996


1996 –   2000











Pre-MedicalSchool at Limburg   UniversityCenter,   Hasselt, Belgium 


MedicalSchool at University   of Antwerp, Antwerp, Belgium (MD)


PhD thesis: “Balance between desired and unwanted effects   of chemotherapeutic and anti-angiogenic drugs” at department of   Medical Oncology at the University    of Groningen, The   Netherlands


Degree: Medical Oncologist, University   of Rotterdam, The Netherlands


Additional training












12th Masterclass in Clinical   Oncology by the European School of

Oncology (ESO) and European   Society of Medical Oncology



Clinical   Trial Statistics for Non-Statisticians by the European

Organization   for Research and Treatment in Cancer (EORTC)


Basic   Course Legislation and Organization for Clinical Researchers




Professional  experience


2008 – 2010



2010 – 2011



2011 –   present




Fellow, Dept of Medical Oncology, ErasmusMedical   Center, Rotterdam,   The Netherlands


Staff member, Dept of Medical Oncology, Radboud   University Nijmegen Medical Centre, Nijmegen,   The Netherlands


Staff member, Dept of Medical Oncology, University of Utrecht,   Utrecht, the Netherlands


Since start of PhD thesis   extensive experience with clinical trials



Research Output (72)

Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma

Clement Paul M J, Dirven Linda, Eoli Marica, Sepulveda-Sanchez Juan M, Walenkamp Annemiek M E, Frenel Jean S, Franceschi Enrico, Weller Michael, Chinot Olivier, De Vos Filip Y F L, Whenham Nicolas, Sanghera Paul, Looman Jim, Kundu Madan G, Peter de Geus Jan, Nuyens Sarah, Spruyt Maarten, Gorlia Thierry, Coens Corneel, Golfinopoulos Vassilis, Reijneveld Jaap C, van den Bent Martin J 15 feb 2021, In: European Journal of Cancer. 147 , p. 1-12 12 p.

Reducing uncertainty:motivations and consequences of seeking a second opinion in oncology

Lehmann Vicky, Smets Ellen M A, de Jong Maxime, de Vos Filip Y F, Kenter Gemma G, Stouthard Jacqueline M, Hillen Marij A 1 dec 2020, In: Acta Oncologica. 59 , p. 1512-1519 8 p.

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors

Gutierrez Martin, Moreno Victor, Heinhuis Kimberley M, Olszanski Anthony J, Spreafico Anna, Ong Michael, Chu Quincy S, Carvajal Richard D, Trigo José, Ochoa de Olza Maria, Provencio Mariano, De Vos Filip, de Braud Filippo, Leong Stephen, Lathers Deanne, Wang Rui, Ravindran Palani, Feng Yan, Aanur Praveen, Melero Ignacio 4 nov 2020, In: Clinical cancer research : an official journal of the American Association for Cancer Research. 27 , p. 460-472 13 p.

Herziene richtlijn ‘Hersenmetastasen’

Hilkens Nina A, Enting Roelien H, Hendriks Lizza E L, Lagerwaard Frank J, de Vos Filip Y F L, Gijtenbeek J M M 8 okt 2020, In: Nederlands Tijdschrift voor Geneeskunde. 164 , p. D5233

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

van Geel Robin M J M, van Brummelen Emilie M J, Eskens Ferry A L M, Huijberts Sanne C F A, de Vos Filip Y F L, Lolkema Martijn P J K, Devriese Lot A, Opdam Frans L, Marchetti Serena, Steeghs Neeltje, Monkhorst Kim, Thijssen Bas, Rosing Hilde, Huitema Alwin D R, Beijnen Jos H, Bernards René, Schellens Jan H M 9 mrt 2020, In: British Journal of Cancer. 122 , p. 1166-1174 9 p.

Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool

Priesterbach-Ackley L P, Boldt H B, Petersen J K, Bervoets N, Scheie D, Ulhøi B P, Gardberg M, Brännström T, Torp S H, Aronica E, Küsters B, den Dunnen W F A, de Vos F Y F L, Wesseling P, de Leng W W J, Kristensen B W 18 feb 2020, In: Neuropathology and Applied Neurobiology. 46 , p. 478-492 15 p.

Efficacy and tolerability of tremelimumab in locally advanced or metastatic urothelial carcinoma patients who have failed first-line platinum-based chemotherapy

Sharma Padmanee, Sohn Joohyuk, Shin Sang Joon, Oh Do Youn, Keam Bhumsuk, Lee Hyo Jin, Gizzi Marco, Kalinka Ewa, de Vos Filip Y.F.L., Ruscica Dario, Ferro Salvatore, Xiao Feng, Baverel Paul, Chen Cecil Chi Keung, Asubonteng Kobby, Morsli Nassim, Dirix Luc 1 jan 2020, In: Clinical Cancer Research. 26 , p. 61-70 10 p.

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

van den Bent Martin, Azaro Analia, De Vos Filip, Sepulveda Juan, Yung W. K.Alfred, Wen Patrick Y., Lassman Andrew B., Joerger Markus, Tabatabai Ghazaleh, Rodon Jordi, Tiedt Ralph, Zhao Sylvia, Kirsilae Tiina, Cheng Yi, Vicente Sergio, Balbin O. Alejandro, Zhang Hefei, Wick Wolfgang 1 jan 2020, In: Journal of Neuro-Oncology. 146 , p. 79-89 11 p.

Cognitive impairments are independently associated with shorter survival in diffuse glioma patients

van Kessel Emma, Huenges Wajer Irene M C, Ruis Carla, Seute Tatjana, Fonville Susanne, De Vos Filip Y F L, Verhoeff Joost J C, Robe Pierre A, van Zandvoort Martine J E, Snijders Tom J 2020, In: Journal of Neurology. 268 , p. 1434-1442 9 p.

Treatment of malignant gliomas with ketogenic or caloric restricted diets: A systematic review of preclinical and early clinical studies

Noorlag Lotte, De Vos Filip Y., Kok Annemieke, Broekman Marike L. D., Seute Tatjana, Robe Pierre A., Snijders Tom J. okt 2019, In: Clinical Nutrition. 38 , p. 1986-1994 9 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet